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A B S T R A C T
Objective: Routine thromboprophylaxis, despite its well‑known effectiveness and the fact 
that venous thromboembolism is a potentially avoidable condition, is not fully established 
in clinical practice. The objectives of the present study were to determine how often 
thromboprophylaxis is used and the presence of thromboembolism risk factors, and to 
verify the appropriateness of its use in medical inpatients, assuming a long‑standing 
national guideline as a parameter.
Methods: This was a retrospective cross‑sectional study, involving inpatients with medical 
conditions in the adult general ward of a faculty hospital. The review was based on a 
defined guideline.
Results: 146  patients were included in the review. At least one risk factor for venous 
thrombo embolism was found in 94.5%. In 130 (89%) patients, prophylactic heparin was 
indicated, and some kind of heparin was prescribed in 73.3%. Regarding the adequacy 
of prophylaxis, 53.4% of prescriptions were correct regarding prophylaxis indication and 
dose; 24% had incorrect dose or frequency of use; 19.2% had no prophylaxis prescription, 
although it was indicated; and in five cases (3.4%), the drug was prescribed, even though it 
was not indicated.
Conclusion: Thromboprophylaxis is underused in this population, and an inappropriate dose 
was prescribed in 50% of cases. Therefore, future studies and interventions should include 
an educational program started from the emergency department care, an essential step to 
bring evidence closer to clinical practice.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Introduction
Venous thromboembolism (VTE) is a group of diseases including 
deep venous thrombosis (DVT), central venous catheter‑related 
thrombosis, thrombosis in different sites, and the most severe 
type, pulmonary thromboembolism (PTE), all of which are 
potentially avoidable causes of morbidity and mortality.1‑4
Hospitalization for a nonsurgical acute disease is associated 
with an eight‑fold rise in VTE risk, representing approximately 
25% of all events assigned to this condition.5 Furthermore, 
postmortem studies demonstrate that approximately 10% 
of inpatient death causes result from pulmonary embolism.6 
Thus, a low degree of clinical suspicion is assumed, considering 
that in part of PTE cases, symptoms are forme fruste.6,7
Most studies on thromboprophylaxis in clinical populations 
involve patients at high risk for a thromboembolic event. 
Recently, studies and guidelines have standardized and 
promoted thromboprophylaxis in medium‑ and low‑risk 
patients.5,8‑11 In this setting, some authors have described 
interventions markedly reducing the risk of VTE in medical 
patients.11,12 An effort of current guidelines has been to 
introduce thromboprophylaxis recommendations for several 
inpatient groups.13‑16
VTE risk stratification is performed by initially considering 
the patient’s age, mobility level, and comorbidities. Individuals 
aged 40 years and over, with reduced mobility and at least one 
additional risk factor (among the following: stroke, cancer, 
central and Swan‑Ganz catheters, bowel inflammatory disease, 
severe respiratory disease, acute rheumatic disease, pregnancy 
and postpartum, previous VTE history, acute myocardial 
infarction [AMI], class III or IV congestive heart failure [CHF], 
age over 55 years, infection [except for thoracic conditions], 
arterial insufficiency, intensive care unit admission, obesity, 
lower limb weakness/paralysis, chemo/hormonal therapy, 
hormone replacement therapy, nephrotic syndrome, and 
thrombophilia) for VTE should be considered at risk. In the 
absence of contraindications, prophylaxis is indicated. For 
individuals under 40 years, specific guidelines should be 
followed.4,10
However, despite the well‑proven benefits, routine 
thromboprophylaxis for medical patients with risk factors is 
poorly established into daily medical practice.17,18 There is 
non‑adherence to consensus and guideline recommendations, 
for which the main reasons are: 1) lack of a systematic assess‑
ment for VTE risk factors and the contraindications for 
heparin use;17,19 2) unawareness of VTE risk, likely favored by 
patients’ diversity; 3) difficult definition for risk factors and 
thromboprophylaxis indication, as well as the several available 
guidelines, resulting in inaccurate and unclear indications 
for thromboprophylaxis.11 This study hypothesized that VTE 
prophylaxis is underused.
The objectives of this study were to retrospectively assess 
medical inpatients at risk of VTE admitted to a general 
medical ward, to define the ratio of medical patients at risk 
of VTE receiving prophylaxis, and to evaluate the adequacy of 
prophylaxis use. The Brazilian Guideline for Venous Thrombo‑
embolism: Prophylaxis in Medical Patients10 a freely available 
publication for the general public based on the local reality 
and approved by several medical societies and the Federal 
Tromboprofilaxia venosa em pacientes clínicos: análise de sua aplicação
R E S U M O
Objetivo: A tromboprofilaxia de rotina, a despeito de sua efetividade estar bem estabelecida 
e o tromboembolismo venoso ser uma condição potencialmente evitável, não se apresenta 
completamente consolidada na prática clínica. Os objetivos do presente estudo são: 1. 
Determinar a frequência da utilização da tromboprofilaxia e presença dos fatores de risco 
para tromboembolismo; 2. Verificar a adequação de sua utilização em pacientes clínicos 
internados, assumindo como parâmetro uma diretriz nacional estabelecida.
Métodos: Estudo retrospectivo transversal envolvendo pacientes internados por doenças 
clínicas em uma enfermaria geral de adultos de um hospital escola. A análise foi baseada 
em diretriz definida.
Resultados: Foram incluídos 146 pacientes para análise. Destes, 94,5% possuíam pelo menos 
um fator de risco para tromboembolismo venoso. Em 130 (89%) pacientes havia indicação 
para uso de heparina profilática, sendo que em 73,3% dos casos estava prescrito algum tipo 
de heparina. Quanto à adequação da profilaxia, 53,4% das prescrições estavam corretas em 
relação à indicação e à dose da profilaxia; 24% apresentavam dose ou frequência incorretas; 
19,2% não tinham prescrição de profilaxia, apesar de ela ser indicada; e em cinco casos 
(3,4%) o fármaco foi prescrito, apesar de não haver indicação.
Conclusão: Existe subutilização da tromboprofilaxia nesta população, com inadequada 
dose prescrita em 50% dos casos. Portanto, estudos e intervenções futuros devem incluir 
um programa educacional que se inicie desde o atendimento em pronto‑socorro, sendo 
essencial para aproximar a evidência à prática clínica.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Palavras‑chave:
Fatores de risco
Fidelidade a diretrizes
Heparina
Profilaxia
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Council of Medicine, aiming to reconcile medical information 
and standardize behaviors aiding reasoning and the decision‑
making process.
Methods
This study was conducted in 2009 and included 187 adult 
patients in a medical ward in the Hospital das Clínicas (HC 
I), a health care reference hospital at the secondary and 
tertiary levels located in the city of Marília, São Paulo, Brazil, 
which provides care for 62 municipalities, with an estimated 
combined population of 1.2 million inhabitants. 
For convenience, the study did not have a probability 
sampling. The analysis was made by review of medical records; 
the patients’ identity was fully preserved. The search period 
was 12 months (January, 2009 to December, 2009), selecting all 
the admissions in the first ten days of four non‑consecutive 
months (January, April, August, and December, 2009). The 
patients were studied in non‑consecutive months in order to 
achieve greater representativeness of the physicians involved 
in care (since the institution is a teaching hospital, where 
physicians in charge of the ward rotate) and a larger range of 
diseases can be found due to seasonal variations.
Data collection was made based on a specific tool, consisting 
of an adaptation of the Brazilian Guideline for Venous 
Thromboembolism: Prophylaxis in Medical Patients.10 Data 
was systematically accessed only once, by two independent 
examiners.
A clinical‑demographic analysis (gender, birth date, 
admission date, and main and secondary diagnosis), a risk 
assessment, and an indication and use of VTE prophylaxis were 
performed, as well as an analysis of the thromboprophylaxis 
used 48 hours after the admission to the medical ward and 
prescription changes up to the end of the hospitalization 
period.
The study inclusion criterion consisted of admission to a 
medical ward, and exclusion criteria were length of stay under 
48 hours, having undergone surgery within a week before the 
admission, use of any type of oral anticoagulant, and VTE 
diagnosis at admission.
The primary outcome was to evaluate the venous 
prophylaxis adequacy based on the recommendations of the 
Brazilian guideline for VTE prophylaxis. 
The following were considered venous thromboprophylaxis 
mandatory indication: 40 years of age and over and reduced 
mobility, associated with at least one risk factor in the absence 
of heparin contraindication.
The doses considered correct for thromboprophylaxis were 
based on the clinical settings in accordance with the Brazilian 
guideline for VTE prophylaxis, and are briefly shown in Table 
1. Any other heparin dose or indication not found in the 
recommendations was considered as inappropriate, such as: 
a) cases with no prophylaxis prescription who required it; b) 
cases where prophylaxis was prescribed, but was unnecessary; 
c) cases with prescribed prophylaxis, but in an inappropriate 
dose or frequency (noncompliant with those recommended by 
the guideline). At the time of the study, the HC I had no formal 
program encouraging VTE prophylaxis in medical patients. The 
Condition Method (level of 
recommendation)
Dose 
Previous history  
  of VTE + risk 
condition
UFH (d) 5,000 IU every 8 h
LMWH (d) Dalteparin  
  or enoxaparin  
(40 mg/day)
Chronic venous  
  insufficiency/ 
varicose veins
Enoxaparin (c) 40 mg/day
Dalteparin (d) 5,000 IU/day
Obesity + risk  
  condition
Enoxaparin (c) 40 mg/day
Dalteparin (d) 5,000 IU/day
Thrombophilias +  
  risk condition
UFH (d) 5,000 IU every 8 h
LMWH (d) Enoxaparin  
  (40 mg/day)
Warfarin INR (2‑3)
HRT/HCC + risk  
  condition
UFH (d) 5,000 IU every 8 h
LMWH (D) Dalteparin  
  or enoxaparin  
(40 mg/day)
CHF UFH (a) 5,000 IU every 8 h
Enoxaparin (a) 40 mg/day
Dalteparin (d) 3,800 IU < 70 kg
Nadroparin (d) 5,700 IU > 70 kg
AMI UFH (a) 5,000 IU every 12 h  
  or full dose
Dalteparin (b) 120 IU/kg
Early walking (b)
ICS (b)
Ischemic stroke UFH (b) 5,000 IU every 8  
  or 12 h
LMWH (a) Enoxaparin  
  (40 mg/day)
ICS
Hemorrhagic stroke Do not use
ARD/BID Enoxaparin (b) 40 mg/day
Dalteparin (b) 5,000 IU/day
SRD UFH (a) 5,000 IU every 8 h
Enoxaparin (b) 40 mg/day
Dalteparin (b) 5,000 IU/day
ICS (b) Uninterrupted
Infections UFH (a) 5,000 IU every  
  8 or 12 h
Enoxaparin (a) 40 mg/day
Dalteparin (b) 5,000 IU/day
Nephrotic syndrome Enoxaparin (b) 40 mg/day
Neoplasms Enoxaparin (b) 40 mg/day
ICU admission UHF (c) 5,000 IU every 12 h
Enoxaparin (d) 40 mg/day
Nadroparin (a) 3,800 or 5,700 IU/day
ICS/IPC
CVC for PN UHF (a) 5,000 IU every 6,  
  12 h or 1 U/mL  
to 3 U/mL in PN
CVC in cancer  
  patients
Dalteparin (b) 2,500 IU/day
Nadroparin (d) 2,850 IU to 7,600 IU/day
 Warfarin (a) 1 mg/day
AMI, acute myocardial infarction; ARD, acute rheumatic diseases; 
CHF, congestive heart failure; CVC, central venous catheters; HCC, 
hormonal contraception; HRT, hormone replacement therapy; 
ICS, intermittent compression stockings; ICU, intensive care unit; 
INR, international normalized ratio; IPC, intermittent pneumatic 
compression; LMWH, low molecular weight heparin, PN, parenteral 
nutrition; SRD, severe respiratory diseases; UFH, unfractionated 
heparin; VTE, venous thromboembolism.
Table 1 – Specific evidence and recommendations  
of venous thromboembolism prophylaxis.
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present study was approved by the Ethics Committee of the 
Medical School of Marília (Famema) in February 22, 2010, under 
protocol No. 050/10
Data were descriptively and inferentially analyzed. 
Central tendency (mean) and dispersion (standard deviation) 
measurements were used to summarize numeric variables. 
Categorical variables (prophylaxis indicated/not indicated; 
use of prophylaxis/no use of prophylaxis; correct/incorrect 
prophylactic dose; prophylaxis change/no prophylaxis 
change during the hospitalization; prophylaxis corrected/
not corrected) were compared through the chi‑squared test. 
Confidence intervals were calculated with a 95% probability, 
and a p‑value < 0.05 was established.
Results
In this study, 146 patients were assessed (Fig. 1). The patients’ 
and the study’s general characteristics are shown in Table 2.
In 130 (89%) patients, prophylactic heparin use was 
indicated; of these, in 107 (73.3%), some kind of heparin was 
prescribed, with 77 (71.9%) using unfractionated heparin 
and 30 (28.1%), low molecular weight heparin. Among those 
using unfractionated heparin, 52 (67.5%) received a dose 
of 5,000 IU every 12 hours, and 25 (32.4%), every 8 hours. 
Among those using low molecular weight heparin, 40 mg 
were prescribed once a day for nine patients (30%); a dose 
of 60 mg every 12 hours was prescribed for ten (33.3%), and 
146 patients
included for 
analysis
8 with no 
risk factors
130 with 
no heparin 
contraindication
8 with 
heparin use 
contraindicated
In 5 cases, 
heparin was 
prescribed
70 on 
unfractionated 
heparin
9 on 
40 mg 
once a day
10 on 
60 mg 
every 12 h
11 with 
other doses
25 using 
5,000 IU
every 8 h
52 using 
5,000 IU
every 12 h 
30 on low 
molecular 
weight heparin
23 with 
no heparin 
prescribed
107 with 
heparin 
prescribed
138 with 
at least one 
risk factor
187 patients
(Initial sample)
29 length of stay < 48 h
seven, VTE diagnosis
two, on anticoagulants
three, missing data
41 patients excluded:
Fig. 1 – Study design. VTE, venous thromboembolism.
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other doses were prescribed for 11 patients (36.6%). No patient 
used VTE mechanical prophylaxis. For patients on heparin 
(unfractionated or low molecular weight heparin) a dosing 
change was observed in 27 (25.2%), with adequacy occurring in 
only five (4.6%) patients with any kind of heparin prescription 
(n = 107).
Regarding prophylaxis adequacy, 78/146 (53.4%) prescrip‑
tions were found to be correct concerning indication and dose, 
35 (24%) had incorrect doses or frequency, 28 (19.2%) had no 
prophylaxis prescription, although it was indicated, and in five 
cases (3.4%), the drug was prescribed, but it was not indicated.
Regarding the studied variables, the frequency of thrombo‑
prophylaxis prescription was higher in patients with a formal 
use indication than in those for whom it was not indicated 
or was even contraindicated (78.5% versus 31.3%, respectively, 
x2 = 16.22; p < 0,001). Among patients who had a prophylaxis 
regimen change, a higher frequency for adequacy of the 
corrected prophylaxis regimen over non‑adequacy (80% versus 
20%, respectively, x2 = 15.9; p < 0.001) was found.
Regarding the prescription of a correct dose for thrombo‑
prophylaxis, no significant statistical difference was observed 
between frequencies for whether prophylaxis was indicated 
or not (36.3% versus 40%, respectively, x2 = 1.14; p = 0.284). 
The same finding was observed when a prophylactic regimen 
change during the clinical course (dose or drug) was compared 
with cases where prophylaxis either was or was not indicated 
(19.8% versus 12.5%, respectively, x2 = 0.49; p = 0.481).
Discussion
The current study evaluated the status of VTE prophylaxis after 
the Brazilian guideline was published.10
Risk factors for VTE are very frequent (94.5% in the 
present study), as observed by studies such as IMPROVE, a 
multicenter study involving 15,156 patients,20 and by the 
observational study ENDORSE, which included 68,183 patients 
and demonstrated that over half of those patients, admitted 
with either surgical or nonsurgical causes, were at risk for 
VTE,21 which warns medical professionals to the attention 
that should be given to this topic. In the present study, the 
high frequency is credited to the fact this study was conducted 
in a tertiary center with a large number of high complexity 
clinical cases.
Regarding venous thromboprophylaxis, a higher rate 
than that found in other studies was observed,22‑27  but 
it was still underused. It can be assumed that the higher 
thromboprophylaxis use was a due to the fact that the study 
was conducted after the disclosure of the Brazilian guide‑
line,10 and also because it was conducted in a teaching hospital 
with a formal internal medicine residency program. However, 
studies conducted so far are controversial on a higher use 
of thromboprophylaxis in teaching hospitals. Chopard et 
al.28 found no difference in hospitals with or without medical 
residency, and Anderson et al.29 showed prophylaxis is most 
often used in teaching hospitals.
However, despite the fact that VTE prophylaxis was more 
often used in the present study, only 53.4% of prescriptions 
were correct regarding prophylaxis indication and dose; 
conversely, 24% had incorrect dose or frequency. This low 
rate of correct prescriptions according to the proposition in the 
Brazilian guideline may be due to the complexity to establish 
the dosing or frequency for the clinical condition, which makes 
the indications particularly individualized. This data draws 
attention to the need for establishing protocols with brief and 
general guidelines regarding correct thromboprophylaxis use, 
as inappropriate doses are often ineffective .
Moreover, in the present study VTE mechanical prophylaxis, 
which has been strengthened as an independent protection to 
prevent bleeding and death in medical patients at risk, was not 
used.30 A higher frequency of unfractionated heparin use was 
also observed, which may represent a local hospital policy or 
the ease of use for the professionals involved.
In this context, Rocha et al.31 has already described that, in 
addition to prophylaxis underuse for medical patients, it does 
not adhere to consensus and guideline recommendations, and 
suboptimal heparin doses are used.
The present findings also suggest that prophylaxis dosing 
regimen changes lead to higher dose adequacy, which could 
be related to the wide range of research material and the 
information exchange between those involved in medical 
patients’ care.
The fact that the HC I does not have a formal program 
or an established guideline for thromboprophylaxis could 
havecontributed to prophylaxis underutilization and prescription 
shortcomings. An increased prophylaxis use from 29% to 52% 
after the introduction of educational strategies was reported by 
Anderson et al.32 Conterno et al.33 showed that preparing and 
implementing a guideline for community‑acquired pneumonia 
promoted therapeutic choice optimization.
The main factors for venous prophylaxis underutilization 
were: 1) lack of systematic assessment of VTE risk factors 
Variables Patients (n = 146)
Mean age, years  
 (range: 2 SD) (min‑max)
61.68 (45.76‑77.6) (18/92)
Age ≥ 40 years 133 (91.1%)
Male gender 94 (64.4%)
Length of stay in hospital: mean,  
 days (range: 2 SD) (min‑max) 
25.95 (1‑65.45) (3/289)
Admission diagnosis
 Infection 43 (29.5%)
 Acute coronary syndrome 21 (14.4%)
 Heart failure 14 (9.6%)
 Stroke 19 (13%)
 Cancer 7 (4.8%)
 Decompensated diabetes 7 (4.8%)
 COPD 4 (2.7%)
 Others 31 (21.2%)
Main diagnosis and RF for VTE 107 (73.3%)
 RF for VTE (≥ 1) 137 (93.8%)
 Heparins contraindicated 10 (6.9%)
COPD, chronic obstructive pulmonary disease; RF, risk factor;  
SD, standard deviation; VTE, venous thromboembolism.
Table 2  – General characteristics of medical inpatients.
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and contraindications for heparin use;17,19 2) lack of aware‑
ness about VTE risk, likely favored by the diversity among 
patients; 3) difficulty in defining risk factors and thrombo‑
prophylaxis indication, as well as the various available guide‑
lines, resulting in inaccurate and unclear indications for 
thromboprophylaxis.11 Thus, incentive policies and inpatients 
assessment systematization are evidently needed.
The preparation of an educational and care program with 
a systematic assessment of patients admitted to the medical 
ward is extremely needed. The definition of cases with 
indication for prophylaxis should start at the emergency room 
through a predetermined flow chart containing clinical and 
epidemiological data, active assessment for risk factors, and 
frequent reassessments.
The need for professional education should be emphasized 
by encouraging journal reading and educational lectures 
where VTE risks, complications, and fatal events are explored. 
Preparation, implementation, and dissemination of venous 
thromboprophylaxis guidelines should be encouraged, 
considering local characteristics.
For this purpose, the authors suggest that every medical 
patient should undergo an initial screening with models similar 
to that proposed by the Brazilian guideline in the emergency 
room or in the medical ward, followed by the utilization of 
predetermined regimens of venous thromboprophylaxis 
according to clinical recommendations (Table 1), thus reducing 
inadequacy risk.
It should also be noted that, as the current study had a 
retrospective and cross‑sectional design, it has methodological 
limitations. Therefore, prospective complementary studies are 
suggested for future development.
Conclusion
VTE prophylaxis underutilization was found in the study 
population. The prescription adequacy (dose and frequency) 
needs to be improved. Venous thromboprophylaxis occurrence 
does not indicate that it is correctly used. It is important to 
disseminate among physicians the guidelines regarding the 
correct manner to indicate and prescribe VTE prophylaxis. 
For this purpose, an educational program starting from the 
emergency room care is essential so that the evidence comes 
closer to clinical practice.
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